학술논문
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, August 2023, 24(8):881-891)
Subject
Language
English
ISSN
14745488
14702045
14702045